Cue Biopharma Overview
Industry: Biotechnology
Sector: Healthcare
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate with Immuno-STAT targeting the KRAS G12V mutation, as well as cancer antigen MAGE-A4; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; and LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts. Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fu Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Cue Biopharma into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $21.9M (reported). Net income was $1.6M (-117% YoY). R&D expense was $16.5M.
Revenue
$21.9M
reported
Net income
$1.6M
-117% YoY
R&D expense
$16.5M
reported
G&A expense
$3.5M
reported
What changed
- Revenue reported to $21.9M.
- Net income -117% YoY to $1.6M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
May 14, 2026
SEC filing
8-K
Mar 16, 2026
SEC filing
10-K
Mar 16, 2026
SEC filing
10-Q
Nov 12, 2025
SEC filing
8-K
Nov 12, 2025
Earnings release
Earnings release
Nov 12, 2025
SEC filing
10-Q
Aug 12, 2025
Earnings release
Earnings release
Aug 12, 2025
SEC filing
8-K
Aug 12, 2025
SEC filing
10-Q
May 12, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
On cue with Kafui DEY: Radio silence
Headline from Business & Financial Times: On cue with Kafui DEY: Radio silence.
On cue with Kafui DEY: Wild guess: Buzzword bomb: The corporate jargon that's putting your audience to sleep — and the fix every executive desperately needs
Headline from Business & Financial Times: On cue with Kafui DEY: Wild guess: Buzzword bomb: The corporate jargon that's putting your audience to sleep — and the fix every executive desperately needs.
These 2 Stocks Are ‘Lagging’ Their Dividends. That’s Our Cue
Headline from Forbes: These 2 Stocks Are ‘Lagging’ Their Dividends. That’s Our Cue.
On cue with Kafui DEY: Wild guess: Why pretending to know the answer could cost you far more than admitting you don't
Headline from Business & Financial Times: On cue with Kafui DEY: Wild guess: Why pretending to know the answer could cost you far more than admitting you don't.
On cue with Kafui DEY: Prep trap: Why over-rehearsing for your next interview could be the worst thing you ever do
Headline from Business & Financial Times: On cue with Kafui DEY: Prep trap: Why over-rehearsing for your next interview could be the worst thing you ever do.
Micron Says Memory Chip Supply Will Remain Tight Beyond 2027. That's Investors' Cue to Load Up on Shares Now.
Headline from The Motley Fool: Micron Says Memory Chip Supply Will Remain Tight Beyond 2027. That's Investors' Cue to Load Up on Shares Now.
Earnings Per Share
Score 4.00/5
Cue Biopharma boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
Return on Equity
Score -0.30/5
Cue Biopharma exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 0.69/5
Cue Biopharma
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 2.96/5
Cue Biopharma
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios